PharmaTalkRadio

In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays.   More specifically, Mike discusses:   How Advarra is leveraging past IRB data sources to identify common causes of site burden, study delays and amendments ...

Tapping into research-naïve sites offers a strategic opportunity to expand patient access. That’s exactly what Endo did when faced with challenges activating sites for their orthopedic study. This case study shares how Endo enabled a new site through hands-on mentorship, infrastructure support, and trust-building— resulting in sustainable partnerships and broader patient reach. How naïve sites can...

AstraZeneca’s US Site Engagement Leads will share how they are reimagining sponsor-site relationships through a trust-first, high-engagement operating model that emphasizes flexibility, responsiveness, and co-creation. This session will showcase how their embedded approach to collaboration has enabled faster site activation, stronger recruitment performance, and improved data delivery—backed by re...

A case study highlighting how Eli Lilly partnered with clinical sites to co-design practical, site-centric solutions that enhanced trial execution and operational efficiency. Fireside Guest: Shafaat Ali Khan Clinical Research Lead (CRL) Director – Investigator Engagement, Eli Lilly & Co Moderator: Jyoti Angal, PhD Director, Clinical Research, Avera McKennan Hospital & University Health Cen...

This case study highlights how Basil Clinical Research and Takeda’s first-time partnership became the top global recruiter, exceeding enrollment goals by tenfold through proactive assessments, early collaboration, and inclusive design. Learn how Takeda’s shift from transactional to strategic, long-term partnerships made this success possible. Identifying and partnering with highpotential sites Inc...

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address:  Integrating connectivity into drug delivery devices as a way to improve patient engagement and adherence How pharma can use drug delivery device data with predictive analytics to forecast demand and optimize production Enabling patient-centric de...

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address how the biopharma and drug delivery industries actively move to embed sustainability into core principles, products and processes. Specifically: How pharma and suppliers can improve sustainability Creating designs with lower carbon footprints relat...

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives discuss specific examples of AI/ML usage by pharma companies through the combination product development process from iteration to commercialization as well as a discussion on how this field will evolve in the coming years. To learn more about the PODD Conference, please visit PODD...

Manufacturing scaleup is a key hurdle in enabling the efficacy of new device technologies. Often this requires a mix of internal and external manufacturing and implementing a commercial control strategy across partners. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma and CDMO executives discuss effective partnering between pharma and manuf...

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss progess in the development of liquid/liquid and liquid/lyo dual chamber systems. Specifically, they address:  Overcoming primary container and autoinjector challenges for liquid-liquid delivery Improving upon dual chamber reconstitution devices Fin...

About this Podcast:  As pharma sponsors continually assesses how to integrate AI into their ways of working, Evinova’s Chief Technology Officer, Sean Connolly, talks about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma. Sean share his thoughts on going for low hanging fruit to encourage adoption, what he's seen...

About this podcast: Recorded at DPHARM 2025, Bayer's Dr Bernhard Glombitza reports on the development, implementation and early impact of their clinical operations reorgnization. He describes how shifting from a traditional hierarchical model to a network of highly empowered teams reduced management layers, broadening the scope of work and changed cross-country operations monitoring.  Dr Glombitza...

About this podcast: In this keynote from Patients as Partners in Clinical Research 2025, Amicus Therapeutics' Chief Patient Advocate, Jayne Gershkowitz, shares how their organization established and embedded patient advocacy into their core structure for lasting impact. More specifically, Ms Gershkowitz focuses on: Defining role standards and recruiting the right talent  Co-creatin research with p...

When designing clinical trials, CMOs aim to answer meaningful questions for a plethora of stakeholders. Inherently, this results in study protocols with more measures, biomarkers and data collection that both provides a platform for strategic decision-making but also impacts patient burden, operational foot-print, timelines and cost. In this panel discussion from the 2025 Chief Medical Officer Sum...

Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery expe...

About this podcast: Recorded at the 2025 DPHARM conference, this state of the union panel convenes site, technology and pharma to discuss:  Different models and the pros and cons of the deployment models What makes a great patient matching solution Predicting what the future growth of this segment looks like The role of AI in this space

About this podcast:  Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timeline...

About this podcast:  Recorded at the 2025 CRAACO meeting, UNC Lineberger’s Comprehensive Cancer Center shares  an initiative to allow local HCPs to still provide clinical care to patients but decentralized research elements to the university system, following the FDA’s change in guidance on Form FDA 1572, which stopped requiring local healthcare professionals (HCPs) involved in DCTs to be listed i...

About this podcast: This podcast, recorded at the 2025 Patients as Partners Europe meeting, addresses how Novo Nordisk is consolidating patient insights to ensure greater knowledge-sharing, data integrity and traceability, addressing the unmet needs of patients, aligning product outcomes with patient expectations, and more.  For more information, go to theconferenceforum.org.  

In this podcast, Kate Woda, Conference Director of the Patients as Partners in Clinical Research conference discusses what attendees can expect at the 13th annual event, including key topic areas, session highlights, presenting companies and more. For more information about the upcoming event, full agenda and speakers, visit patientsaspartnersconference.com .

In this podcast, featuring a panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs with recent M&A and partnership experience share those experiences as well as how CMOs of other small to midsize emerging biotech companies can support the conversations and operations that take place throughout the process of business development. Specifically: Different kinds of BD deals to be...

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss conjugation and bioconjugation approaches to make ASOs and small molecules more tolerable while improving targeting. Technologies discussed include ADCs, PDCs, SMDCs, VDCs, RDCs and AOCs. Specifically they address: Biological and chemical challenge...

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° about how to strategically approach hiring FTEs, insourcing, outsourcing and contracting to be appropriately prepared for the different stages of a biotech companies development from preclinical to early stage to late stage trials to commercialization. Specifically: Balancing the mix of hires and outsourcing H...

While lipid nanoparticles are the most clinically advanced drug delivery system for nucleic acid therapeutics, they are only one tool in a toolbox of potential delivery vehicles. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss additional tools, including polymeric nanoparticles, protein-based na...

About this podcast:  This podcast comes from the DPHARM 2025 meeting. Pfizer details how they jointly co-designed and implemented an EDC/CDMS platform that’s fit for purpose, and analysis data set. This session focuses on: Engaging all stakeholders in designing the platform The evolution of the platform focus: the transition from the majority of data coming from EDC to 3/4 of the data from third p...